• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>Janus

Janus

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA)

    XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA)

  2. UPDATE: Pimco close to settling lawsuit brought by Bill Gross: WSJ

    UPDATE: Pimco close to settling lawsuit brought by Bill Gross: WSJ

  3. Flows + Bloat = Headaches for Funds

    Goldilocks knows there are problems with being too hot or too cold.

  4. Financials Down With Treasury Rates -- Financials Roundup

    Financials Down With Treasury Rates -- Financials Roundup

  5. Fed's Caution Propels Euro to One-Month High -- Update

    Fed's Caution Propels Euro to One-Month High -- Update

  6. UPDATE: Bill Gross says another credit crisis could be just around the corner

    UPDATE: Bill Gross says another credit crisis could be just around the corner

  7. Bill Gross says another credit crisis could be just around the corner

    Bill Gross says another credit crisis could be just around the corner

  8. Janus Capital's Bill Gross trying to short credit to reverse four decades of instinct

    Janus fund has returned 1.7% since Mr. Gross took over in 2014.

  9. Janus Capital's Bill Gross says only the Federal Reserve can save us

    Janus bond manager pushes for 'helicopter money' pronto

  10. Bill Gross' Janus fund reaps biggest inflow in more than a year

    Janus Global Unconstrained received about $144 million in May.

12345

©2017 Morningstar Advisor. All right reserved.